MY207529A - Use of pediococcus acidilactici gka4 in preparation of composition for preventing or treating renal dysfunction - Google Patents
Use of pediococcus acidilactici gka4 in preparation of composition for preventing or treating renal dysfunctionInfo
- Publication number
- MY207529A MY207529A MYPI2023001857A MYPI2023001857A MY207529A MY 207529 A MY207529 A MY 207529A MY PI2023001857 A MYPI2023001857 A MY PI2023001857A MY PI2023001857 A MYPI2023001857 A MY PI2023001857A MY 207529 A MY207529 A MY 207529A
- Authority
- MY
- Malaysia
- Prior art keywords
- gka4
- preventing
- renal dysfunction
- preparation
- composition
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Tires In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure provides a use of a novel Pediococcus acidilactici GKA4 in preparation of a composition for preventing or treating renal dysfunction, which refers to the renal dysfunction caused by cisplatin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW112103672A TWI849717B (en) | 2023-02-02 | 2023-02-02 | Use of manufacturing a composition of pediococcus acidilactici gka4 for preventing and treating the renal function impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY207529A true MY207529A (en) | 2025-03-03 |
Family
ID=92261095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2023001857A MY207529A (en) | 2023-02-02 | 2023-04-05 | Use of pediococcus acidilactici gka4 in preparation of composition for preventing or treating renal dysfunction |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP7553634B2 (en) |
| MY (1) | MY207529A (en) |
| TW (1) | TWI849717B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119745931B (en) * | 2024-12-25 | 2025-12-05 | 广西爱生生命科技有限公司 | Application of Pediococcus pentosaceus A21243 in lowering blood uric acid and improving renal function |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7935334B2 (en) | 2005-07-07 | 2011-05-03 | Imagilin Technologies, LLC | Probiotics as alternative medicines against infectious diseases |
| CN101172118A (en) | 2006-07-26 | 2008-05-07 | 美国医迈科技有限公司 | Probiotics as alternative medicines against infectious diseases |
| TWI807609B (en) * | 2020-05-06 | 2023-07-01 | 葡萄王生技股份有限公司 | Use of lactic acid bacteria for increasing resistance against enterovirus 71 |
-
2023
- 2023-02-02 TW TW112103672A patent/TWI849717B/en active
- 2023-04-04 JP JP2023060896A patent/JP7553634B2/en active Active
- 2023-04-05 MY MYPI2023001857A patent/MY207529A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202432153A (en) | 2024-08-16 |
| TWI849717B (en) | 2024-07-21 |
| JP2024110378A (en) | 2024-08-15 |
| JP7553634B2 (en) | 2024-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000081A (en) | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors. | |
| MX2020000178A (en) | Synergistic compositions. | |
| PH12020551205A1 (en) | Fap inhibitors | |
| SA520411125B1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| MX2023000025A (en) | Hpk1 inhibitors and uses thereof. | |
| MX2019015580A (en) | Methods for treating huntington's disease. | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| PH12018501669A1 (en) | Compositions containing tucaresol or its analogs | |
| JOP20170192A1 (en) | Cyclic dinucleotide | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| MX373763B (en) | USE OF A SUSTAINED-RELEASE COMBINATION COMPOSITION OF ACAMPROSATE AND BACLOFEN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS. | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| MX2024013215A (en) | Compounds for inhibiting kif18a | |
| MA37866A1 (en) | Aza-indazole or diaza-indazole derivatives for the treatment of pain | |
| MX2021012501A (en) | Prc2 inhibitors. | |
| TW201613874A (en) | Benzimidazol-2-amines as mIMH1 inhibitors | |
| MX2022001863A (en) | Ripretinib for treating gastrointestinal stromal tumors. | |
| MX2009004984A (en) | Methods for preserving renal function using xanthine oxidoreductase inhibitors. | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| MX2021008651A (en) | GADOLINIUM COMPLEX AND A DISTEREOISOMERICALLY ENRICHED PCTA-DERIVED CHELATING LIGAND AND METHOD OF PREPARATION AND PURIFICATION. | |
| CR20240014A (en) | Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors | |
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| EA202091684A1 (en) | NEW GALACTOSIDE GALECTIN INHIBITOR | |
| MY207529A (en) | Use of pediococcus acidilactici gka4 in preparation of composition for preventing or treating renal dysfunction | |
| PH12022552489A1 (en) | V delta1+ t cells for the treatment of myeloid malignancies |